American Association for Cancer Research
15357163mct170309-sup-181601_3_supp_4265299_hw6p89.pdf (111.59 kB)

Supplementary Table and Supplementary Figures 1-2 from The Irreversible Covalent Fibroblast Growth Factor Receptor Inhibitor PRN1371 Exhibits Sustained Inhibition of FGFR after Drug Clearance

Download (111.59 kB)
journal contribution
posted on 2023-04-03, 14:43 authored by Eleni Venetsanakos, Ken A. Brameld, Vernon T. Phan, Erik Verner, Timothy D. Owens, Yan Xing, Danny Tam, Jacob LaStant, Kwan Leung, Dane E. Karr, Ronald J. Hill, Mary E. Gerritsen, David M. Goldstein, Jens Oliver Funk, J. Michael Bradshaw

Supplementary Table S1. Percentage of enzyme activity following dialysis compared to a non-compound treated control; Supplementary Figure S1. PRN1371 inhibited SNU16 cell proliferation as assessed by BrdU incorporation; Supplementary Figure S2. PRN1371 treatment induces apoptosis via caspase activation.



An increasing number of cancers are known to harbor mutations, translocations, or amplifications in the fibroblast growth factor receptor (FGFR) family of kinases. The FGFR inhibitors evaluated in clinical trials to date have shown promise at treating these cancers. Here, we describe PRN1371, an irreversible covalent inhibitor of FGFR1-4 targeting a cysteine within the kinase active site. PRN1371 demonstrated strong FGFR potency and excellent kinome-wide selectivity in a number of biochemical and cellular assays, including in various cancer cell lines exhibiting FGFR alterations. Furthermore, PRN1371 maintained FGFR inhibition in vivo, not only when circulating drug levels were high but also after the drug had been cleared from circulation, indicating the possibility of sustained FGFR inhibition in the clinic without the need for continuous drug exposure. Durable tumor regression was also obtained in multiple tumor xenografts and patient-derived tumor xenograft models and was sustained even using an intermittent dosing strategy that provided drug holidays. PRN1371 is currently under clinical investigation for treatment of patients with solid tumors. Mol Cancer Ther; 16(12); 2668–76. ©2017 AACR.

Usage metrics

    Molecular Cancer Therapeutics



    Ref. manager